Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
2024
2023
2022
2021
2020
2019
-
Nov 02,2023
HuidaGene Therapeutics Announces First Patient Dosed in Multnational Phase 1/2 Trial of HG004 for Inherited Blindness
Learn More
-
Oct 31,2023
U.S. FDA Awards Both Rare Pediatric Disease and Orphan Drug Designations to HG204, a CRISPR RNA-editing Therapy, for the Treatment of MECP2 Duplication Syndrome
Learn More
-
Oct 26,2023
HuidaGene Therapeutics Announces Last Patient Dosed in Clinical Trial of HG004 for the Treatment of Leber Congenital Amaurosis
Learn More
-
Oct 09,2023
HuidaGene Therapeutics Announces 13 Presentations at the Upcoming European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
Learn More
-
Sep 14,2023
HuidaGene Showcases Gene-Editing Based Medicine for Neurological Disease at Japan Society of Gene and Cell Therapy 2023 Annual Meeting
Learn More
-
Sep 06,2023
HuidaGene Therapeutics Announces First Patient Dosed Of The World's First Novel CRISPR/Cas13 RNA-Editing Therapy HG202 For Neovascular Age-related Macular Degeneration
Learn More
-
Aug 07,2023
HuidaGene Therapeutics Receives FDA Rare Pediatric Disease Designation for HG004 to Treat Inherited Blindness
Learn More
-
Aug 04,2023
HuidaGene and Kactus Announce Strategic Collaboration and License Agreement to Promote Commercialization of Next-Generation Gene Editing Enzyme, hfCas12Max®
Learn More
-
May 25,2023
HuidaGene Therapeutics Appoints Alvin Luk as Chief Executive Officer
Learn More